NO20073943L - Monoklonale antistoffer mot CD30 som mangler fukosylrester. - Google Patents
Monoklonale antistoffer mot CD30 som mangler fukosylrester.Info
- Publication number
- NO20073943L NO20073943L NO20073943A NO20073943A NO20073943L NO 20073943 L NO20073943 L NO 20073943L NO 20073943 A NO20073943 A NO 20073943A NO 20073943 A NO20073943 A NO 20073943A NO 20073943 L NO20073943 L NO 20073943L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- fucosyl residues
- monoclonal antibodies
- lacking
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SAMMENDRAG Oppfinnelsen angår anti-CD30 antistoffer som mangler fucosyl-rester. Antistoffene ifølge oppfinnelsen viser økt antistoffavhengig cellulær cytotoksisitet (ADCC) aktivitet, omfattende evnen til å lysere CD30-uttrykkende cellelinjer som ikke blir lysert av den fucosylerte formen av antistoffene. Oppfinnelsen tilveiebringer også vertsceller som uttrykker anti-CD30 antistoffene som mangler fucosyl-rester, hvor vertscellene mangler en fucosyl transferase. Fremgangsmåter for anvendelse av antistoffene for å hemme veksten av CD30+-celler, slik som tumorceller, tilveiebringes også.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65419705P | 2005-02-18 | 2005-02-18 | |
PCT/US2006/005854 WO2006089232A2 (en) | 2005-02-18 | 2006-02-17 | Monoclonal antibodies against cd30 lacking fucosyl residues |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073943L true NO20073943L (no) | 2007-11-14 |
Family
ID=36636549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073943A NO20073943L (no) | 2005-02-18 | 2007-07-27 | Monoklonale antistoffer mot CD30 som mangler fukosylrester. |
Country Status (16)
Country | Link |
---|---|
US (2) | US8207303B2 (no) |
EP (1) | EP1848745B1 (no) |
JP (2) | JP2008530244A (no) |
KR (1) | KR101323455B1 (no) |
CN (1) | CN101128486A (no) |
AU (1) | AU2006214033B2 (no) |
BR (1) | BRPI0607203A2 (no) |
CA (1) | CA2598561C (no) |
ES (1) | ES2498794T3 (no) |
IL (1) | IL184950A (no) |
MX (1) | MX2007009940A (no) |
NO (1) | NO20073943L (no) |
NZ (1) | NZ560209A (no) |
RU (1) | RU2492186C2 (no) |
SG (1) | SG170006A1 (no) |
WO (1) | WO2006089232A2 (no) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
MX2007003533A (es) | 2004-10-01 | 2007-05-23 | Medarex Inc | Metodos de tratar linfomas cd30 positivas. |
US8207303B2 (en) * | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
CA2660795C (en) * | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
EP2311493A4 (en) * | 2008-05-20 | 2012-09-26 | Kaneka Corp | CYTOTOXIC COMPOSITION |
WO2011039150A1 (en) * | 2009-10-02 | 2011-04-07 | Roche Glycart Ag | A-fucosylation detection in antibodies |
CA2829110C (en) * | 2011-03-06 | 2019-01-15 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
KR102023496B1 (ko) | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
EP2812702B1 (en) * | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
CN105407921A (zh) * | 2013-03-13 | 2016-03-16 | 赛诺菲 | 包含抗cd38抗体和卡非佐米的组合物 |
ES2798307T3 (es) * | 2013-03-15 | 2020-12-10 | Hoffmann La Roche | Composiciones de cultivo de células con antioxidantes y procedimientos para la producción de polipéptidos |
DK3708583T3 (da) * | 2013-08-01 | 2022-05-16 | Five Prime Therapeutics Inc | Ikke-fucosylerede anti-fgfr2iiib-antistoffer |
EP2876114A1 (en) | 2013-11-25 | 2015-05-27 | Consejo Superior De Investigaciones Científicas | Antibodies against CCR9 and applications thereof |
CA2924448C (en) * | 2013-11-29 | 2021-12-14 | Genentech, Inc. | Antibody selection apparatus and methods |
US10022453B2 (en) | 2013-12-23 | 2018-07-17 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
DK3194583T3 (da) * | 2014-07-30 | 2021-12-20 | Zumutor Biologics Inc | Ikke-fucosyleret protein og fremgangsmåder dermed |
US11033637B2 (en) | 2014-11-21 | 2021-06-15 | University Of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
EP3590961A1 (en) * | 2015-03-25 | 2020-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
MX2017017172A (es) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
US11951175B2 (en) | 2016-02-08 | 2024-04-09 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
WO2017137423A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Improved sulfamide linkers for use in bioconjugates |
EP3413915A1 (en) * | 2016-02-08 | 2018-12-19 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates |
RU2018136778A (ru) | 2016-03-24 | 2020-04-24 | Байер Фарма Акциенгезельшафт | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
MX2018016404A (es) | 2016-06-21 | 2019-10-15 | Teneobio Inc | Anticuerpos de union a cd3. |
RS65595B1 (sr) | 2016-09-14 | 2024-06-28 | Teneoone Inc | Antitela koja vezuju cd3 |
BR112019012883A2 (pt) | 2016-12-21 | 2019-11-26 | Bayer Ag | conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis |
CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
WO2018237006A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS |
WO2018237037A2 (en) | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA |
KR20220020810A (ko) | 2019-06-14 | 2022-02-21 | 테네오바이오, 인코포레이티드 | Cd22와 cd3에 결합하는 다중특이적 중쇄 항체 |
WO2021221927A1 (en) | 2020-04-27 | 2021-11-04 | Parsons Corporation | Narrowband iq signal obfuscation |
EP4186564A1 (en) | 2020-04-29 | 2023-05-31 | Teneoone, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
EP4161563A1 (en) | 2020-06-05 | 2023-04-12 | Tessa Therapeutics Ltd. | Treatment of cd30-positive cancer |
JP2020202832A (ja) * | 2020-07-10 | 2020-12-24 | ツムトー バイオロジクス、インコーポレイテッド | 非フコシル化タンパク質および方法 |
CA3218235A1 (en) | 2021-04-27 | 2022-11-03 | Baylor College Of Medicine | Virus-specific immune cells expressing chimeric antigen receptors |
CN112986164B (zh) * | 2021-05-18 | 2021-08-24 | 上海执诚生物科技有限公司 | 一种抗肝素稳定的α-L-岩藻糖苷酶检测试剂盒及其应用 |
TW202321443A (zh) | 2021-10-26 | 2023-06-01 | 新加坡商泰莎治療有限公司 | 用於生產編碼car之反轉錄病毒載體的細胞株 |
TW202328438A (zh) | 2021-12-08 | 2023-07-16 | 新加坡商泰莎治療有限公司 | 淋巴瘤之治療 |
WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
WO1991007437A2 (en) | 1989-11-20 | 1991-05-30 | Parker, David, L. | Improved cd-30 antibodies and fragments thereof |
US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
DE4200043A1 (de) | 1991-11-11 | 1993-05-13 | Stein Harald Prof Dr | Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren |
CA2131003A1 (en) | 1992-05-26 | 1993-12-09 | Raymond G. Goodwin | Novel cytokine that binds cd30 |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
AU4953693A (en) | 1992-08-25 | 1994-03-15 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
CA2210620C (en) | 1995-01-18 | 2004-06-22 | Boehringer Mannheim Gmbh | Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen |
DE19543039C1 (de) | 1995-11-08 | 1996-11-21 | Medac Klinische Spezialpraep | Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30 |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
WO1999040187A1 (de) | 1998-02-06 | 1999-08-12 | Hinrich Abken | Nukleinsäuren zur modulation zellulärer aktivierung |
DE19937264A1 (de) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
DE60035337T2 (de) * | 2000-05-12 | 2008-02-28 | Gpc Biotech Ag | Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoider Tumorzellen, herbeiführen oder bewirken |
US7016788B2 (en) | 2000-07-07 | 2006-03-21 | Curagen Corporation | Methods for classifying nucleic acids and polypeptides |
US6652854B2 (en) | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
AU2001285286A1 (en) | 2000-08-29 | 2002-03-13 | Noveon Ip Holdings Corp. | Hydrogels containing substances |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
JPWO2003000286A1 (ja) * | 2001-06-22 | 2004-10-07 | 第一サントリーファーマ株式会社 | 好酸球増多性疾患治療薬 |
NZ592087A (en) * | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
EP1471938A4 (en) * | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
US7470775B2 (en) | 2002-06-07 | 2008-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
EP2248892B1 (en) * | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
WO2005014651A1 (ja) | 2003-08-11 | 2005-02-17 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗hm1.24抗体 |
MX2007003533A (es) * | 2004-10-01 | 2007-05-23 | Medarex Inc | Metodos de tratar linfomas cd30 positivas. |
US8207303B2 (en) * | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
-
2006
- 2006-02-17 US US11/918,178 patent/US8207303B2/en not_active Expired - Fee Related
- 2006-02-17 EP EP06720888.4A patent/EP1848745B1/en active Active
- 2006-02-17 JP JP2007556370A patent/JP2008530244A/ja active Pending
- 2006-02-17 MX MX2007009940A patent/MX2007009940A/es active IP Right Grant
- 2006-02-17 RU RU2007134661/10A patent/RU2492186C2/ru not_active IP Right Cessation
- 2006-02-17 ES ES06720888.4T patent/ES2498794T3/es active Active
- 2006-02-17 BR BRPI0607203-8A patent/BRPI0607203A2/pt not_active IP Right Cessation
- 2006-02-17 AU AU2006214033A patent/AU2006214033B2/en not_active Ceased
- 2006-02-17 WO PCT/US2006/005854 patent/WO2006089232A2/en active Application Filing
- 2006-02-17 NZ NZ560209A patent/NZ560209A/en not_active IP Right Cessation
- 2006-02-17 SG SG201101192-1A patent/SG170006A1/en unknown
- 2006-02-17 CA CA2598561A patent/CA2598561C/en not_active Expired - Fee Related
- 2006-02-17 CN CNA2006800053568A patent/CN101128486A/zh active Pending
- 2006-02-17 KR KR1020077021247A patent/KR101323455B1/ko not_active IP Right Cessation
-
2007
- 2007-07-27 NO NO20073943A patent/NO20073943L/no not_active Application Discontinuation
- 2007-07-31 IL IL184950A patent/IL184950A/en not_active IP Right Cessation
-
2012
- 2012-05-02 US US13/462,566 patent/US8491898B2/en active Active
-
2013
- 2013-01-10 JP JP2013002702A patent/JP2013116900A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2598561C (en) | 2014-01-21 |
KR101323455B1 (ko) | 2013-10-29 |
ES2498794T3 (es) | 2014-09-25 |
CN101128486A (zh) | 2008-02-20 |
CA2598561A1 (en) | 2006-08-24 |
RU2492186C2 (ru) | 2013-09-10 |
US20100021479A1 (en) | 2010-01-28 |
US8207303B2 (en) | 2012-06-26 |
WO2006089232A2 (en) | 2006-08-24 |
AU2006214033B2 (en) | 2011-08-11 |
EP1848745B1 (en) | 2014-07-09 |
MX2007009940A (es) | 2007-10-10 |
US8491898B2 (en) | 2013-07-23 |
NZ560209A (en) | 2009-04-30 |
KR20070107770A (ko) | 2007-11-07 |
JP2013116900A (ja) | 2013-06-13 |
US20120251533A1 (en) | 2012-10-04 |
IL184950A (en) | 2011-04-28 |
SG170006A1 (en) | 2011-04-29 |
AU2006214033A1 (en) | 2006-08-24 |
WO2006089232A3 (en) | 2007-03-29 |
EP1848745A2 (en) | 2007-10-31 |
RU2007134661A (ru) | 2009-03-27 |
BRPI0607203A2 (pt) | 2009-08-25 |
JP2008530244A (ja) | 2008-08-07 |
IL184950A0 (en) | 2007-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073943L (no) | Monoklonale antistoffer mot CD30 som mangler fukosylrester. | |
NO20074063L (no) | Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier | |
WO2007084672A3 (en) | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues | |
MX2008016039A (es) | Preparacion de glucano. | |
MX350903B (es) | Anticuerpos anti-cd38. | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
MX2009004986A (es) | Metodos de tratamiento de anemia hemolitica. | |
AU2006226733A8 (en) | Antibodies against CD38 for treatment of multiple myeloma | |
MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
WO2010056898A3 (en) | Rapid expression cloning of human monoclonal antibodies from memory b cells | |
MY162791A (en) | Anti-il-23 antibodies | |
NO20064034L (no) | Makrolider og fremgangsmater for a fremstille disse | |
NO20083062L (no) | Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1 | |
MY195289A (en) | Anti IL-36R Antibodies | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
WO2008019148A3 (en) | Tumor suppression using placental stem cells | |
MY153710A (en) | Humanized c-kit antibody | |
RS51954B (en) | CRYSTAL MODIFICATIONS OF PYRACLOSTROBIN | |
NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
WO2005074607A3 (en) | Method of treating hemolytic disease | |
GEP20125398B (en) | Human monoclonal antibodies to activin receptor-like kinase-1 | |
MX2012002458A (es) | Anticuerpos anti-cdcp1 humanizados. | |
MY170720A (en) | Antibody formulations | |
WO2008085221A3 (en) | Therapeutic use of cd31 expressing cells | |
NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MEDAREX LLC, US |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |